Surgery and Laser Therapy for Bilateral Glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study explores the use of surgical debulking and/or laser-induced thermal therapy (LITT) to treat butterfly glioblastomas that involve both hemispheres. Eligible participants have a presumptive bilateral GBM with a residual component under 2.5 cm and a good performance status. Treatments may include surgery, LITT, medications started or planned, or careful observation according to current guidelines. The trial is led by King’s College Hospital with collaboration from Medtronic and focuses on feasibility, safety, and potential impact on outcomes. The design emphasizes real-world applicability in a specialized neuro-oncology setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Presumptive diagnosis of bGBM as per preoperative MRI and MDT assessment
2. Presumed residual / smaller component of the bGBM has to be \< 2.5cm
3. Performance Status 0-1
4. Able to consent for the study

Exclusion Criteria:

1. bGBM measuring \>2.5 cm in both hemispheres.
2. Tumour progression between surgical debulking and LITT treatment
3. Severe complications after surgery (hydrocephalus, infection, heamatoma, stroke)

Where it's running

• King's College NHS Foundation Trust
  London, United Kingdom Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• How Acetadote might affect metabolism in newly diagnosed glioblastoma

  This early-phase trial tests whether Acetadote can change brain tumor metabolism in adults with a new glioblastoma diagnosis.

  Recruiting Early Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07387666

• Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII

  This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.

  Recruiting at 38 sites Phase 2 Black Diamond Therapeutics, Inc. · Birmingham, Alabama and 37 other locations · NCT07326566

• Standard temozolomide plus 5‑ALA and low‑intensity ultrasound after surgery for newly diagnosed glioblastoma

  This trial tests whether adding the light‑activated drug 5‑ALA together with a low‑intensity ultrasound device to standard temozolomide can help people with newly diagnosed glioblastoma after surgery and chemoradiation.

  Recruiting at 11 sites Phase 2 Alpheus Medical, Inc. · Boston, Massachusetts and 10 other locations · NCT07225621

• Focused ultrasound to open the blood-brain barrier in adults with high-grade glioma on chemotherapy

  This trial tests whether focused ultrasound using the Next Generation Dome Helmet can safely open the blood-brain barrier in adults with glioblastoma who are receiving maintenance temozolomide chemotherapy.

  Recruiting Phase 1 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07179328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.